Titre:
  • Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Auteur:Trøseid, Marius; Hites, Maya
Informations sur la publication:Critical care, 27, 1, 9
Statut de publication:A Paraître, 2023-12-31
Sujet CREF:Soins intensifs réanimation
Mots-clés:Baricitinib
COVID-19
Safety
Vaccination
Note générale:SCOPUS: ar.j
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1364-8535
info:doi/10.1186/s13054-022-04205-8
info:scp/85146105672
info:pmid/36627655